Welcome to our dedicated page for Histogen news (Ticker: HSTO), a resource for investors and traders seeking the latest updates and insights on Histogen stock.
Histogen Inc (HSTO) is a clinical-stage biotechnology company pioneering regenerative medicine solutions through its proprietary fibroblast-derived therapies. This page serves as the definitive source for verified corporate announcements, research developments, and strategic updates directly from Histogen and authorized partners.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements related to Histogen’s two core product platforms: embryonic-like protein complexes and exceltrix extracellular matrix technology. All content is curated to meet strict journalistic standards for accuracy in financial reporting.
The news collection includes earnings disclosures, partnership announcements, intellectual property updates, and progress reports on therapeutic applications targeting inflammatory and apoptotic pathways. Content is organized chronologically to enable tracking of the company’s evolving position within the regenerative medicine sector.
Bookmark this page for streamlined access to Histogen’s official communications, or check back regularly to monitor developments in their innovative approach to biologically-derived therapeutics. For historical context, all press materials remain archived and searchable.
Histogen Inc. (NASDAQ: HSTO) reported Q3 2021 financials, highlighting a revenue increase driven by a one-time sale of conditioned medium (CCM) to Allergan. Product revenues rose to $0.6 million from $0.4 million, while service revenues dropped to zero due to completed obligations. R&D expenses increased to $2.3 million. The company is progressing in its clinical pipeline, with an IND filing for HST 004 expected in Q3 2022 and top-line results for HST 003 anticipated in Q4 2022. Current cash reserves stand at $19.2 million, expected to last into December 2022.
Histogen Inc. (NASDAQ: HSTO) has announced the appointment of Steven J. Mento, Ph.D., as Executive Chairman and Interim President and CEO, effective immediately. David Crean, Ph.D., continues as Lead Independent Director after Richard Pascoe stepped down from his role. Mento, with over 35 years in biotechnology, aims to leverage Histogen's innovative technology to enhance restorative therapeutics. The company focuses on developing first-in-class treatments using cell conditioned media for various therapeutic applications, including joint and tissue repair.
Histogen Inc. (NASDAQ: HSTO) announced positive findings from its Phase 1 study of emricasan in mild COVID-19 patients, demonstrating a favorable safety profile and significant clinical improvements. Results will be presented by Amerimmune's CEO, Dr. Oral Alpan, at the American College of Allergy, Asthma, and Immunology conference on November 6, 2021. Emricasan, a pan-caspase inhibitor, showed potential in reducing inflammation and facilitating faster recovery, positioning it as a promising treatment compared to standard approaches. Histogen anticipates advancing its clinical development through partnerships.
Histogen Inc. (NASDAQ: HSTO) announced the upcoming release of its financial results for Q3 2021, scheduled for November 10, 2021, after market closure. The company specializes in developing first-in-class restorative therapeutics aimed at enhancing natural bodily repair processes. Utilizing hypoxia-induced multipotent cells, Histogen's technology platform addresses various therapeutic needs, including joint cartilage regeneration and soft tissue repair.
Histogen Inc. (NASDAQ: HSTO) has announced that its CEO, Richard W. Pascoe, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on-demand starting at 7:00 AM ET. Histogen focuses on developing innovative restorative therapeutics that aim to stimulate the body's natural repair processes. Their technology includes cell-conditioned media and extracellular matrix materials aimed at treating various conditions such as joint cartilage and soft tissue repair.
Histogen Inc. (NASDAQ: HSTO) and Amerimmune, LLC announced findings from their Phase 1 study of emricasan for treating mild COVID-19. The study showed emricasan was safe, with significant improvements in hematological and immune markers, leading to symptom resolution in patients by day 7. A p-value of p<0.007 indicates strong statistical significance. The study enrolled 13 patients due to declining COVID-19 cases in NYC. Histogen aims to develop a Phase 2 strategy for emricasan while exploring commercialization opportunities.
Histogen Inc. (HSTO) reported strategic shifts in its regenerative medicine focus during Q2 2021, emphasizing orthopedic product development, specifically HST 003 for cartilage regeneration and HST 004 for spinal disc repair. The company initiated a Phase 1/2 study of HST 003 and is advancing IND enabling activities for HST 004. Additionally, positive results from a Phase 1 study of Emricasan in mild COVID-19 patients were announced. However, revenues fell nearly 100% to $5,000, highlighting financial challenges, despite a cash position of $23.1 million to sustain operations through Q4 2022.
Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, is set to present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 2:00 p.m. Eastern Time. Richard W. Pascoe, President and CEO, will lead the presentation, which will focus on the company’s innovative restorative therapeutics aimed at enhancing biological function. For those unable to attend live, a replay will be available for 90 days on Histogen's investors page.
Histogen Inc. (NASDAQ: HSTO) has announced that its financial results for the second quarter will be released after the market closes on August 11, 2021. The company focuses on developing innovative restorative therapeutics aimed at promoting the body’s natural healing processes. Histogen’s technology utilizes cell-conditioned media and extracellular matrix materials, with applications in areas such as joint cartilage regeneration and hair growth.
Histogen Inc. (NASDAQ: HSTO) has initiated a Phase 1/2 clinical trial for HST 003, a treatment aimed at regenerating hyaline cartilage in the knee through the application of human extracellular matrix (hECM) in conjunction with a microfracture procedure. Participating clinical sites include OasisMD, The Steadman Clinic, and Walter Reed Medical Center. This double-blind, placebo-controlled trial will assess safety and efficacy using MRI and outcome scores like KOOS and IKDC. HST 003 has shown promising results in preclinical studies, indicating potential for various orthopedic applications.
FAQ
What is the current stock price of Histogen (HSTO)?
What is the market cap of Histogen (HSTO)?
